Researchers in Germany have discovered that mitoxantrone-used to treat aggressive, relapsing, or progressive multiple sclerosis-can increase the risk of leukemia and colorectal cancer in those being treated.
Following a median follow-up of more than 8 years, researchers in Germany have discovered that mitoxantrone—used to treat aggressive, relapsing, or progressive multiple sclerosis (MS)—can increase the risk of leukemia and colorectal cancer (CRC) in those being treated.
Published in the journal Neurology, the authors of the study conducted by researchers at the
University of Würzburg in Germany, retrospectively observed 677 patients who were administered mitoxantrone for their MS, between 1994 and 2007. Follow-up data, gathered till 2010 for 676 patients, included malignancies, life status, and cause of death.
During the median follow-up period of 8.7 years (interquartile range, 6.8-11.2), 37 patients were diagnosed with a malignancy: either breast cancer (9 patients), CRC (7 patients), acute myeloid leukemia (AML, 4 patients), or other (1 or 2 patients). Following a comparison with the German national cancer registry, the authors reported standardized incidence ratio of CRC at 2.98 (95% CI, 1.20-6.14) and of AML 10.44 (95% CI, 3.39-24.36). Of the reported 55 deaths, 12 patients died of a malignancy.
Risk factors, the authors found, included age at treatment initiation as a significant risk factor for developing malignancies. Sex, cumulative dose of mitoxantrone, or treatment with other immunosuppressive agents did not seem to play a role in increasing the patient’s risk of developing a malignancy.
Explaining the significance of their findings, lead author Mathias Buttmann, MD, of the University of Würzburg, said in a statement, “Despite an increased risk of acute myeloid leukemia and colorectal cancer, the overall rate of cancer was low enough to justify still using this drug for people severely affected by MS if no better treatment is available. Mitoxantrone is the only approved treatment for people with secondary progressive MS without relapses and should be considered in people where the disease is evolving quickly. Also, many of the new and highly effective MS drugs are not available to people in a number of countries for economic reasons, so mitoxantrone is being used for people with very active relapsing forms of the disease.”
Citing the small sample size of their study as a limitation, Buttmann advised that additional studies are needed to confirm their findings. He also recommended that if their results are confirmed, patients being treated with mitoxantrone should undergo colonoscopy so they would be diagnosed earlier.
Reference
Buttmann M, Seuffert L, Mäder U, Toyka KV. Malignancies after mitoxantrone for multiple sclerosis [published online May 11, 2016]. Neurology. doi:http:/​/​dx.​doi.​org/​10.​1212/​WNL.​0000000000002745.
Real-World Study Reveals Key Insights into DLBCL Treatment Patterns, Outcomes
April 18th 2024A recent study offers valuable insights into the characteristics, treatment patterns, and outcomes of diffuse large B-cell lymphoma (DLBCL) in patients across different lines of therapy, providing a look into the landscape of DLBCL management.
Read More
Pegcetacoplan for PNH More Cost-Effective Than Anti-C5 Monoclonal Antibodies
April 18th 2024A cost-utility analysis conducted from the perspective of the Italian health system found that pegcetacoplan was more effective and less costly than 2 complement 5 (C5) inhibitors for the treatment of paroxysmal nocturnal hemoglobinuria (PNH).
Read More
Oncology Onward: A Conversation With Penn Medicine's Dr Justin Bekelman
December 19th 2023Justin Bekelman, MD, director of the Penn Center for Cancer Care Innovation, sat with our hosts Emeline Aviki, MD, MBA, and Stephen Schleicher, MD, MBA, for our final episode of 2023 to discuss the importance of collaboration between academic medicine and community oncology and testing innovative cancer care delivery in these settings.
Listen
Many Patients With Psoriasis in Clinical Trials Experience Nocebo Effects, Study Finds
April 18th 2024Half of patients exposed to placebo in clinical trials experienced adverse events (AEs), which may be partially explainable by nocebo effects, according to a recent review and meta-analysis.
Read More
Low-Volume Hospitals Had Higher Reoperation Rate, Postoperative Complications in CRC
April 18th 2024Patients opting for elective colorectal surgery to address colorectal cancer (CRC) could have different rates of reoperation and postoperative complications based on the size of the hospital.
Read More